Holen Sie sich die Stockscreener-App
18.65
6.89%
-1.38
Handel nachbörslich:
18.70
0.05
+0.27%
Schlusskurs vom Vortag:
$20.03
Offen:
$20.04
24-Stunden-Volumen:
366.40K
Relative Volume:
1.03
Marktkapitalisierung:
$1.27B
Einnahmen:
$350.00K
Nettoeinkommen (Verlust:
$-72.78M
KGV:
-17.27
EPS:
-1.08
Netto-Cashflow:
$-54.46M
1W Leistung:
-14.57%
1M Leistung:
-18.91%
6M Leistung:
+14.63%
1J Leistung:
+12.42%
1-Tages-Spanne:
$18.54
$20.17
1-Wochen-Bereich:
$18.54
$21.67
52-Wochen-Spanne:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
18.65 | 1.37B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
MSN Money - MSN
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript - AOL.com
Pulse Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript - The Motley Fool
Pulse Biosciences Reports Q1 2026 Financial Results and Business Updates, Highlighting $0.4 Million Revenue from nPulse Vybrance and Clinical Progress 1535 - Minichart
Pulse Biosciences (PLSE) Reports Strong Q1 Performance - GuruFocus
Pulse Biosciences, Inc (PLSE) reports Q1 loss, lags revenue estimates - MSN
Pulse Biosciences 1Q Loss/Shr 27c >PLSE - Moomoo
Pulse Biosciences Highlights Q1 Results, Electrophysiology Focus - TipRanks
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Pullback And Ongoing Losses - Sahm
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results - BioSpace
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Pulse Biosciences Q1 Loss Widens - marketscreener.com
Earnings Flash (PLSE) Pulse Biosciences Posts Q1 Loss $0.27 a Share, vs. FactSet Est of $0.32 Loss - marketscreener.com
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q1 Revenue $401,000, vs. FactSet Est of $250,000 - marketscreener.com
Pulse Biosciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
BRIEF-Pulse Biosciences Q1 Net Income USD -18.581 Million - TradingView
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Executive pay and 71% insider stake at Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.9%What's Next? - MarketBeat
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst CallSlideshow (NASDAQ:PLSE) 2026-04-27 - Seeking Alpha
Med-tech companies highlight PFA data as competition intensifies - BioWorld News
Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data - TipRanks
New nPulse atrial fibrillation data for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026 - BioSpace
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Pulse Biosciences (PLSE) Reports Promising Clinical Results for Cardiac Catheter System - GuruFocus
Assessing Pulse Biosciences (PLSE) Valuation After Positive nPulse Cardiac Catheter Study Update - Sahm
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Upd - The National Law Review
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026 - Investing News Network
Pulse Biosciences announces positive clinical data from Npulse cardiac catheter system - marketscreener.com
Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System - TradingView
Pulse Biosciences to Host Analyst Event on April 25, 2026 - Investing News Network
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story - Yahoo Finance
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network
Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus
Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - ChartMill
Pulse Biosciences' NPulse Technology to Be Featured at the Heart Rhythm Society 2026 Annual Meeting - 富途牛牛
Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18Asset Allocation - Xã Vĩnh Công
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks
Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView
Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):